HALO®

PHARMACEUTICALS

USP Itraconazole System Suitability Comparison

335





TEST CONDITIONS:

Column: FPP 100 Å C18, 3 µm, 4.6 x 100 mm
Column: HALO 90 Å C18, 2 µm, 2.1 x 50 mm
Part Number: 91812-402
Mobile Phase A: 27.2 g/L of Tetrabutylammonium Hydrogen Sulfate in Water
Mobile Phase B: ACN
Flow Rate: 1.5 mL/min (4.6 mm)
0.5 mL/min (2.1 mm)
Pressure: 307 bar/4.6 mm
455 bar/2.1 mm
Temperature: 30°C
Detection: UV 225 nm, PDA
Injection Volume: 10 µL (4.6 mm)
1 µL (2.1 mm)
Sample Solvent: 0.4% HCl in Methanol
Data Rate: 100 Hz
Response Time: 0.025 sec.
Flow Cell: 1 µL
Instrument: Shimadzu Nexera X2

Gradients:

FPP C18, 3 µm 4.6 x 100 mm:

Time	%B
0.00	20
2.00	20
22.00	50
27.00	50

HALO 90 Å C18 2 µm 2.1 x 50 mm:

Time	%B
0.00	20
0.55	20
6.00	50
7.37	50

PEAK IDENTITIES

1. 4-Triazolyl Isomer
2. Propyl analog
3. Isopropyl analog
4. Epimer
5. Itraconazole
6. n-Butyl isomer
7. Didioxolanyl analog

Itraconazole is an antifungal medication used for the treatment of various fungal and yeast infections. With the newly approved <621> guidance for allowable changes to USP gradient methods, the method for itraconazole system suitability which was official as of 01-May-2020 from USP can be optimized to save time, reduce solvent consumption, and reduce sample if needed. The method specifies a 4.6 x 100 mm, 3 µm L1 column. By changing to a shorter length and smaller ID column with smaller particle size (HALO 90 Å, 2 µm, 2.1 x 50 mm), the total run time is reduced by more than 3 times and solvent consumption is reduced by 11 times. Even with these changes, the HALO® column passes the system suitability requirement of peak-to-valley ratio by 2 times the minimum. Additionally, the amount of sample injected is reduced from 10 µL to 1 µL. HALO® Fused-Core® technology enables USP gradient methods to be optimized for both time and solvent savings.

advancedmaterialstechnology

Made in the USA | halocolumns.com

INNOVATION YOU CAN TRUST,
PERFORMANCE YOU CAN RELY ON